Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2026)
Artiva Biotherapeutics (ARTV) reported Income from Continuing Operations of 23518000.0 for Q1 2026, down 15.81% year-over-year from 27935191.04 in Q1 2025, and down 13.23% quarter-over-quarter from 20770000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Income from Continuing Operations data on file, last reported at 23518000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 23518000.0, down 15.81% year-over-year; the trailing twelve-month figure through Mar 2026 was 87062000.0 (down 27.28% YoY), and the FY2025 annual result was 83851000.0, down 28.27% from the prior year.
- Income from Continuing Operations retreated to 23518000.0 in Q1 2026 per ARTV's latest filing, from 20770000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 13251000.0 in Q4 2023 and troughed at 23518000.0 in Q1 2026.
- A 4-year average of 13011583.33 and a median of 16289500.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations tumbled 246.84% in 2024, then decreased 15.81% in 2026.
- A 4-year view of Income from Continuing Operations shows it stood at 13251000.0 in 2023, then sank by 221.42% to 16090000.0 in 2024, then declined by 29.09% to 20770000.0 in 2025, then slipped by 13.23% to 23518000.0 in 2026.
- Business Quant data shows ARTV's Income from Continuing Operations at 23518000.0 in Q1 2026, 20770000.0 in Q4 2025, and 21525000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Artiva Biotherapeutics | 241.85 Mn | 241.85 Mn | - | -23.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.52 Mn |
| Dec 31, 2025 | -20.77 Mn |
| Sep 30, 2025 | -21.53 Mn |
| Jun 30, 2025 | -21.25 Mn |
| Mar 31, 2025 | -20.31 Mn |
| Dec 31, 2024 | -16.09 Mn |
| Sep 30, 2024 | -16.49 Mn |
| Jun 30, 2024 | -15.51 Mn |
| Mar 31, 2024 | -13.84 Mn |
| Dec 31, 2023 | 13.25 Mn |
| Sep 30, 2023 | 11.23 Mn |
| Jun 30, 2023 | -11.32 Mn |